ライフサイエンスコーパス: plasminogen activator inhibitor 1

1 s is either weak (interleukin-8) or delayed (plasminogen activator inhibitor-1).

2 es the uPA, its receptor, and its inhibitor (plasminogen activator inhibitor-1).

3 tor) and matrix metalloproteinase inhibitor (plasminogen activator inhibitor-1).

4 r slows down matrix degradation by increased plasminogen activator inhibitor 1.

5 overexpression of alpha-SMA, but not CTGF or plasminogen activator inhibitor 1.

6 xpression of the endogenous Smad target gene plasminogen activator inhibitor-1.

7 ue growth factor, collagen-alpha1[Iota], and plasminogen activator inhibitor-1.

8 or pathway inhibitor, fibrinogen-like 1, and plasminogen activator inhibitor-1.

9 nd to S195A tPA that is already complexed to plasminogen activator inhibitor-1.

10 ants without affecting the protein levels of plasminogen activator inhibitor-1.

11 pus by inducing expression of its inhibitor, plasminogen activator inhibitor-1.

12 ssociated with impeded fibrinolysis, such as plasminogen activator inhibitor-1.

13 s, such as beta-galactosidase (beta-Gal) and plasminogen activator inhibitor-1.

14 sion as well as that of the uPA receptor and plasminogen activator inhibitor-1.

15 (NO*) production and increased expression of plasminogen activator inhibitor-1.

16 ols, with significantly higher CNS levels of plasminogen activator inhibitor-1.

17 tissue inhibitor of metalloproteinase-1 and plasminogen activator inhibitor-1.

18 itivity, C-reactive protein, fibrinogen, and plasminogen activator inhibitor-1.

19 nectin, X-linked inhibitor of apoptosis, and plasminogen activator inhibitor-1.

20 y upregulating the serine protease inhibitor plasminogen activator inhibitor-1.

21 There was a 51.8% net decrease in PAI-1 (plasminogen activator inhibitor-1), a 12.1% net decrease

22 crease in interleukin-8, a 21.4% decrease in plasminogen activator inhibitor-1, a 51.3% decrease in t

23 n of CAGE led to the decreased expression of plasminogen activator inhibitor-1, a TGFbeta-responsive

24 evented CRP-induced arteriolar expression of plasminogen activator inhibitor-1, a thrombogenic protei

25 issue repair and vascular integrity, such as plasminogen activator inhibitor-1, activin A, and cystei

26 ad decreased ADAMTS-13 activity, but similar plasminogen activator inhibitor-1 activity and prothromb

27 c peptide) and lower blood concentrations of plasminogen activator inhibitor-1, aldosterone, C-reacti

28 Plasminogen activator inhibitor-1 also induced neurite e

29 -regulation of the production and release of plasminogen activator inhibitor-1, an inhibitor of the p

30 xpression of the TGFbeta-regulated promoters plasminogen activator inhibitor 1 and 3TP, increased Sma

31 rombin, and factor V); fibrinolytic factors (plasminogen activator inhibitor 1 and lipoprotein(a)); p

32 owed less fibrosis and blocked expression of plasminogen activator inhibitor 1 and osteopontin 1.

33 Higher circulating plasminogen activator inhibitor-1 and aldosterone levels

34 On backward elimination, plasminogen activator inhibitor-1 and aldosterone remain

35 Plasminogen activator inhibitor-1 and C-reactive protein

36 Adjusting for S100B did not alter plasminogen activator inhibitor-1 and E-selectin associa

37 A similar trend was observed with plasminogen activator inhibitor-1 and extracellular matr

38 mes and hyperfibrinolysis with low levels of plasminogen activator inhibitor-1 and high D-dimer level

39 and mRNA expression of profibrotic markers: plasminogen activator inhibitor-1 and monocyte chemotact

40 TGF-beta signaling through up-regulation of plasminogen activator inhibitor-1 and phosphorylation of

41 both murine models while decreasing alveolar plasminogen activator inhibitor-1 and promoting myofibro

42 Plasminogen activator inhibitor-1 and protein C had a sy

43 formed stable inhibitory complexes with both plasminogen activator inhibitor-1 and protein C inhibito

44 Measurement of plasminogen activator inhibitor-1 and protein-C levels m

45 nd was completely abrogated by the urokinase plasminogen activator inhibitor-1 and serine protease in

46 ass index, such that the increased levels of plasminogen activator inhibitor-1 and soluble VCAM-1 ass

47 odest phenotypes, but mice deficient in both plasminogen activator inhibitor-1 and thrombin-activatab

48 ferentiation and stabilization, most notably plasminogen activator inhibitor-1 and thrombospondin-1.

49 ed expression of the prothrombotic molecules plasminogen activator inhibitor-1 and tissue factor (TF)

50 sal expression of alpha-smooth muscle actin, plasminogen activator inhibitor-1 and transforming growt

51 tor and histidine-rich glycoprotein, but not plasminogen activator inhibitors 1 and 2.

52 of prometastatic (i.e. cyclooxygenase-2 and plasminogen activator inhibitor-1) and prosurvival (i.e.

53 ent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), and 15 were new disc

54 (D-dimer, tissue-type plasminogen activator, plasminogen activator inhibitor-1), and inflammation (in

55 Tests for FXI and FXII activity, plasminogen activator inhibitor 1, and activated partial

56 receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multipara

57 lammatory cytokines such as TNF-alpha, IL-6, plasminogen activator inhibitor 1, and IL-1beta.

58 1-mediated induction of fibronectin, Snail1, plasminogen activator inhibitor 1, and matrix metallopro

59 to a reduction in the proteolytic inhibitor, plasminogen activator inhibitor-1, and an associated thr

60 ndividually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related

61 1+2, fibrinogen, thrombomodulin, protein C, plasminogen activator inhibitor-1, and D-dimers.

62 tologic changes and expression of TGF-beta1, plasminogen activator inhibitor-1, and extracellular mat

63 protein cholesterol, albumin excretion rate, plasminogen activator inhibitor-1, and hemoglobin A1c le

64 d2 phosphorylation, normalized expression of plasminogen activator inhibitor-1, and mitigated PH and

65 lammatory markers, e.g., C-reactive protein, plasminogen activator inhibitor-1, and other cytokines,

66 s of insulin, triglycerides, blood pressure, plasminogen activator inhibitor-1, and the ratio of tota

67 pression of interleukin-6, thrombospondin-1, plasminogen activator inhibitor-1, and tissue factor, wh

68 associated with inhibition of TGF-beta1 and plasminogen activator inhibitor-1, and with a significan

69 d plasma tissue plasminogen activator (tPA), plasminogen-activator inhibitor 1, and von Willebrand fa

70 4, a protein with relevant interactions with plasminogen activator inhibitor-1, angiogenesis, and wou

71 asma tissue plasminogen activator (t-PA) and plasminogen-activator inhibitor 1 antigen and activity c

72 lammatory markers were then studied (sCD40L, plasminogen activator inhibitor 1, antithrombin III, and

73 6, endothelin-1, matrix metalloproteinase-9, plasminogen activator inhibitor-1, Bax and caspase-3, pr

74 on of tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1, both regulators of fi

75 ed with uPA and MCF-7 cells treated with uPA-plasminogen activator inhibitor-1 complex, proliferation

76 PA in MS lesions because of formation of tPA-plasminogen activator inhibitor-1 complexes reduces capa

77 Mean plasminogen activator inhibitor 1 concentrations decreas

78 key markers of TGFbeta activation, including plasminogen activator inhibitor-1, connective tissue gro

79 We measured plasma concentrations of plasminogen activator inhibitor-1, E-selectin, and angio

80 Preincubation of vitronectin with plasminogen activator inhibitor-1 eliminated its ability

81 tion, proliferation, collagen synthesis, and plasminogen activator inhibitor-1 expression in cardiac

82 ase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 expression was predomi

83 alpha-smooth muscle actin, fibronectin, and plasminogen activator inhibitor-1 expression, but it did

84 alpha-smooth muscle actin, fibronectin, and plasminogen activator inhibitor-1 expression.

85 elial cells decreased angiotensin II-induced plasminogen activator inhibitor-1 expression.

86 with increased alpha-smooth muscle actin and plasminogen activator inhibitor-1 expression.

87 ipids, apoB, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, fasting and post-gluc

88 flammation (C-reactive protein), hemostasis (plasminogen activator inhibitor-1, fibrinogen), neurohor

89 etic peptide and B-type natriuretic peptide, plasminogen activator inhibitor-1, fibrinogen, and homoc

90 on of genes downstream of Smad2/3, including plasminogen activator inhibitor-1, fibronectin, and conn

91 ions traditionally associated with different plasminogen activator inhibitor-1 functions apply to the

92 Transcriptional changes in the Tgf-beta1 and plasminogen activator inhibitor 1 gene products were mea

93 ciate with the endogenous TGFbeta-responsive Plasminogen Activator Inhibitor-1 gene promoter in a TGF

94 Increased activated plasminogen activator inhibitor 1 had a strong associati

95 on to its critical function in fibrinolysis, plasminogen activator inhibitor-1 has been implicated in

96 king BDNF maturation in the hippocampus with plasminogen activator inhibitor 1 hinders the persistenc

97 assays for 6 biomarkers (C-reactive protein, plasminogen activator inhibitor-1, homocysteine, aldoste

98 osidase activity and increased expression of plasminogen activator inhibitor 1 in human breast cancer

99 s and levels of the coagulation intermediary plasminogen activator inhibitor 1 in three mouse models

100 e liver by 2 hours, and the concentration of plasminogen activator inhibitor-1 in plasma increased be

101 easurement of plasma levels of protein C and plasminogen activator inhibitor-1 in plasma samples that

102 h enalapril or losartan also decreased renal plasminogen activator inhibitor-1 in TSLPtg mice, assess

103 aused similar (p = NS) increases in inactive plasminogen-activator inhibitor 1 in both smokers and no

104 oatrial natriuretic peptide, fibrinogen, and plasminogen activator inhibitor-1) in nonobese Framingha

105 ependent connective tissue growth factor and plasminogen activator inhibitor-1-induced proliferative

106 or antigen, surfactant protein D, protein C, plasminogen activator inhibitor-1, interleukins 6 and 8,

107 Plasminogen activator inhibitor-1 is the main physiologi

108 s by infusion of blocking antibodies against plasminogen activator inhibitor-1 led to decreased lung-

109 ctivity were decreased due to an increase in plasminogen activator inhibitor-1 levels in transfusion-

110 matrix metalloproteinase (MMP)-8, MMP-9, and plasminogen activator inhibitor-1 levels were determined

111 eline protein-C levels were low and baseline plasminogen activator inhibitor-1 levels were elevated i

112 nce of circulating alteplase and recovery of plasminogen activator inhibitor-1 levels within 2 hours

113 in complex, tissue plasminogen activator and plasminogen activator inhibitor-1 (markers for fibrinoly

114 e (including procollagen I, TGF-beta(1), and plasminogen activator inhibitor-1 mRNA), suggesting that

115 eactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activa

116 C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activi

117 en/fibrin degradation products and a rise in plasminogen activator inhibitor 1 occurred between 4 and

118 hrombin dimers and in serum concentration of plasminogen activator inhibitor-1 occurred before the on

119 Conversely, treatment with plasminogen activator inhibitor-1 or neutralizing antibo

120 Mice deficient in plasminogen activator inhibitor-1 or thrombin-activatabl

121 binding (P<0.0001) without affecting plasma plasminogen-activator inhibitor 1 or von Willebrand fact

122 Inhibition of uPA activity with natural (plasminogen activator inhibitor-1) or synthetic (amilori

123 whereas downregulation of thrombomospondin, plasminogen activator inhibitor 1, or connective tissue

124 tor, but did not influence thrombomospondin, plasminogen activator inhibitor 1, or connective tissue

125 bronectin 1 (P<0.0001), perforin (P=0.0002), plasminogen activator inhibitor 1 (P=0.0002), transformi

126 combined therapy attenuated the formation of plasminogen activator inhibitor-1 (p < 0.05), IL-1beta,

127 Higher plasminogen activator inhibitor-1 (p = 0.002), E-selecti

128 Similarly, higher plasminogen activator inhibitor-1 (p = 0.007) and S100B

129 Plasminogen activator inhibitor-1 (P=0.014), interleukin

130 lesterol, P < .001; triglycerides, P < .001; plasminogen activator inhibitor 1, P for trend = .04; an

131 Increased expression of plasminogen activator inhibitor -1 (PAI-1) in adipose ti

132 the role of the serine proteinase inhibitor plasminogen activator inhibitor -1 (PAI-1) in facilitati

133 The goal was to determine whether plasminogen activator inhibitor 1 (PAI-1) and fibrinolyt

134 ive protein (CRP), interleukin 6 (IL-6), and plasminogen activator inhibitor 1 (PAI-1) and to explore

135 HOE-140 also abolished the increase in plasminogen activator inhibitor 1 (PAI-1) antigen observ

136 the protective and proliferative effects of plasminogen activator inhibitor 1 (PAI-1) deficiency aft

137 Increased plasminogen activator inhibitor 1 (PAI-1) has been linke

138 ates the interaction between vitronectin and plasminogen activator inhibitor 1 (PAI-1) in a variety o

139 Plasminogen activator inhibitor 1 (PAI-1) is a serpin in

140 Transcriptional regulation of plasminogen activator inhibitor 1 (PAI-1) is of particul

141 c TGF-beta1 mRNA, tissue hydroxyproline, and plasminogen activator inhibitor 1 (PAI-1) levels were si

142 potent and selective synthetic antagonist of plasminogen activator inhibitor 1 (PAI-1) that preserved

143 insulin response element in the promoter of plasminogen activator inhibitor 1 (PAI-1) that was activ

144 (MS, n = 20; control, n = 10), expression of plasminogen activator inhibitor 1 (PAI-1), a key enzyme

145 hich H. pylori upregulates the expression of plasminogen activator inhibitor 1 (PAI-1), a member of t

146 of JNK and p38 as well as the expression of plasminogen activator inhibitor 1 (PAI-1), a TGF-beta-re

147 diated proteolysis, which is counteracted by plasminogen activator inhibitor 1 (PAI-1), another secre

148 vator (tPA) and its physiological inhibitor, plasminogen activator inhibitor 1 (PAI-1), in Puumala ha

149 with diabetes experience elevated levels of plasminogen activator inhibitor 1 (PAI-1), regardless of

150 The aim of this study is to evaluate serum plasminogen activator inhibitor 1 (PAI-1), tumor necrosi

151 isolated a high-quality DNA aptamer pair for plasminogen activator inhibitor 1 (PAI-1).

152 ral function for the gene SERPINE1, encoding plasminogen activator inhibitor 1 (PAI-1).

153 VFA and higher plasma IL-6, adiponectin, and plasminogen activator inhibitor 1 (PAI-1).

154 The most upregulated gene identified encodes plasminogen activator inhibitor 1 (PAI-1, Serpine 1), a

155 Plasminogen activator inhibitor 1 (PAI-1/serpinE1) can b

156 n), factor VII G10976A, prothrombin G20210A, plasminogen activator inhibitor-1 (PAI-1) [-675] 4G/5G,

157 As plasminogen activator inhibitor-1 (PAI-1) accentuates ce

158 ay inhibitor (TFPI) expression and increased plasminogen activator inhibitor-1 (PAI-1) activity in th

159 oactive epitopes of tPA are regulated by the plasminogen activator inhibitor-1 (PAI-1) and by a PAI-1

160 n TGF-beta-induced Smad3 phosphorylation and plasminogen activator inhibitor-1 (PAI-1) and cyclooxyge

161 ide new evidence that both overexpression of plasminogen activator inhibitor-1 (PAI-1) and elevated c

162 n of incident diabetes to dynamic changes of plasminogen activator inhibitor-1 (PAI-1) and fibrinogen

163 -beta1 induces transcriptional activation of plasminogen activator inhibitor-1 (PAI-1) and growth inh

164 he brain correlates with the upregulation of plasminogen activator inhibitor-1 (PAI-1) and inhibition

165 catabolism is increased after inhibition of plasminogen activator inhibitor-1 (PAI-1) and may consti

166 ve systematically examined the affinities of plasminogen activator inhibitor-1 (PAI-1) and proteinase

167 l transition (EMT), TNBC cells could produce plasminogen activator inhibitor-1 (PAI-1) and stimulate

168 contains the high-affinity binding sites for plasminogen activator inhibitor-1 (PAI-1) and the urokin

169 n effects, including increased production of plasminogen activator inhibitor-1 (PAI-1) and tissue fac

170 Concentrations of OPN, as well as plasminogen activator inhibitor-1 (PAI-1) and vascular e

171 Plasminogen activator inhibitor-1 (PAI-1) and vitronecti

172 intimal growth through early upregulation of plasminogen activator inhibitor-1 (PAI-1) and, subsequen

173 mostatic markers of endothelial dysfunction, plasminogen activator inhibitor-1 (PAI-1) antigen, and v

174 Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated

175 ctivatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) are causal fac

176 Plasma levels of plasminogen activator inhibitor-1 (PAI-1) are elevated i

177 Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are important

178 Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are proteins t

179 In vitro, TSP1 acutely induces expression of plasminogen activator inhibitor-1 (PAI-1) by monocytic c

180 asure tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) by real-time P

181 The inactivation of plasminogen activator inhibitor-1 (PAI-1) by the small m

182 ons between genetic variants and circulating plasminogen activator inhibitor-1 (PAI-1) concentration,

183 adherin and induced Snail1, fibronectin, and plasminogen activator inhibitor-1 (PAI-1) expression.

184 oxide synthase (eNOS) expression and reduced plasminogen activator inhibitor-1 (PAI-1) expression.

185 nvolved in the estrogen-dependent control of plasminogen activator inhibitor-1 (PAI-1) gene expressio

186 onsensus XRE (NC-XRE) in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene that recr

187 Plasminogen activator inhibitor-1 (PAI-1) has been impli

188 y binding site in human vitronectin (VN) for plasminogen activator inhibitor-1 (PAI-1) has been local

189 While the pathogenesis of VOD is uncertain, plasminogen activator inhibitor-1 (PAI-1) has emerged as

190 epidermal growth factor receptor (EGFR) and plasminogen activator inhibitor-1 (PAI-1) have a shorter

191 The role of plasminogen activator inhibitor-1 (PAI-1) in angiogenesi

192 Although the involvement of plasminogen activator inhibitor-1 (PAI-1) in fibrotic di

193 Basal expression of plasminogen activator inhibitor-1 (PAI-1) in human and m

194 ited MKK3-p38 kinase-dependent expression of plasminogen activator inhibitor-1 (PAI-1) in lung, there

195 Recent studies suggest a crucial role for plasminogen activator inhibitor-1 (PAI-1) in mediating s

196 fect of intracerebroventricular injection of plasminogen activator inhibitor-1 (PAI-1) in rat pups su

197 Levels of plasminogen activator inhibitor-1 (PAI-1) increased sign

198 en activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) into the early

199 Plasminogen activator inhibitor-1 (PAI-1) is a biomarker

200 The serpin plasminogen activator inhibitor-1 (PAI-1) is a potential

201 Plasminogen activator inhibitor-1 (PAI-1) is a serpin cl

202 Plasminogen activator inhibitor-1 (PAI-1) is an importan

203 Plasminogen activator inhibitor-1 (PAI-1) is increased i

204 Plasminogen activator inhibitor-1 (PAI-1) is known to mo

205 Plasminogen activator inhibitor-1 (PAI-1) is known to pr

206 Although plasminogen activator inhibitor-1 (PAI-1) is known to st

207 Locally increased amplification of plasminogen activator inhibitor-1 (PAI-1) is largely res

208 Plasminogen activator inhibitor-1 (PAI-1) is the main in

209 Plasminogen activator inhibitor-1 (PAI-1) is the major i

210 flammatory cytokines, the chemokine IL-8 and plasminogen activator inhibitor-1 (PAI-1) levels as well

211 lthough numerous studies have shown elevated plasminogen activator inhibitor-1 (PAI-1) levels in kelo

212 okinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) levels in the

213 ively define common genetic variation at the plasminogen activator inhibitor-1 (PAI-1) locus and rela

214 ty of uPA or deficiency of the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) might cause ca

215 he morning surge of the prothrombotic factor plasminogen activator inhibitor-1 (PAI-1) observed in hu

216 gands specific to alpha-helix F (alphaHF) of plasminogen activator inhibitor-1 (PAI-1) on the stoichi

217 g element 4-luciferase and 3TP-luciferase (a plasminogen activator inhibitor-1 (PAI-1) promoter const

218 king p53 (p53-/-) express minimal amounts of plasminogen activator inhibitor-1 (PAI-1) protein as wel

219 TGF-beta1 activity was evaluated using a plasminogen activator inhibitor-1 (PAI-1) reporter trans

220 glomerular fibrin deposition and glomerular plasminogen activator inhibitor-1 (PAI-1) staining than

221 mer, tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) were associate

222 iation of a gain-of-function polymorphism in plasminogen activator inhibitor-1 (PAI-1) with airway ob

223 l)amino-7-nitrobenz-2-oxa-3-diazole (NBD) P9 plasminogen activator inhibitor-1 (PAI-1) with tissue-(t

224 Elevated levels of plasminogen activator inhibitor-1 (PAI-1), a potent inhi

225 Deficiency in plasminogen activator inhibitor-1 (PAI-1), an endogenous

226 t gene SERPINE1 that is encoding the protein plasminogen activator inhibitor-1 (PAI-1), an establishe

227 Plasma and tissue levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor

228 y expressed increased basal levels of SPARC, plasminogen activator inhibitor-1 (PAI-1), and active be

229 , vascular endothelial growth factor (VEGF), plasminogen activator inhibitor-1 (PAI-1), and endotheli

230 NADPH oxidases (NOXs), and fibrotic markers, plasminogen activator inhibitor-1 (PAI-1), and fibronect

231 VEGF, plasminogen activator inhibitor-1 (PAI-1), and pigment e

232 trol studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelys

233 nase-9 (MMP-9), tumor necrosis factor-alpha, plasminogen activator inhibitor-1 (PAI-1), and urinary o

234 cyclin-dependent kinase inhibitor p21CIP and plasminogen activator inhibitor-1 (PAI-1), by Ang II is

235 active protein (CRP), serum amyloid A (SAA), plasminogen activator inhibitor-1 (PAI-1), creatine kina

236 ipids, apoB, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1 (PAI-1), fasting and p

237 okinase type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1), keloid fibrob

238 ese changes paralleled reduced expression of plasminogen activator inhibitor-1 (PAI-1), PDGF-B (PDGF-

239 ed for seven adipokines-adiponectin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin, hep

240 In infected mice that overexpress plasminogen activator inhibitor-1 (PAI-1), S. aureusclfA

241 ctor receptors (sTNFR-I and -II), protein C, plasminogen activator inhibitor-1 (PAI-1), surfactant pr

242 investigated the relationship of ceramide to plasminogen activator inhibitor-1 (PAI-1), the primary i

243 ificant increases in the renal expression of plasminogen activator inhibitor-1 (PAI-1), vascular endo

244 Protein levels of one of these, plasminogen activator inhibitor-1 (PAI-1), were tested a

245 Plasminogen activator inhibitor-1 (PAI-1), which inhibit

246 the inactivation of tPA and two chain uPA by plasminogen activator inhibitor-1 (PAI-1), which is pote

247 leomycin failed to induce miR-34a in p53- or plasminogen activator inhibitor-1 (PAI-1)-deficient mice

248 76.5% decrease; P<0.01), whereas hearts from plasminogen activator inhibitor-1 (PAI-1)-null mice rele

249 tions and is characterized by high levels of plasminogen activator inhibitor-1 (PAI-1).

250 een shown that ethanol induces activation of plasminogen activator inhibitor-1 (PAI-1).

251 asminogen activator (tPA), and up-regulating plasminogen activator inhibitor-1 (PAI-1).

252 xia-inducible factor-1alpha (HIF-1alpha) and plasminogen activator inhibitor-1 (PAI-1).

253 generate breakdown products of matrix-bound plasminogen activator inhibitor-1 (PAI-1).

254 nhibited the TGF-beta1 and Smad3 target gene plasminogen activator inhibitor-1 (PAI-1).

255 rimary inhibitor of endogenous thrombolysis, plasminogen activator inhibitor-1 (PAI-1).

256 n vitro binding to and inactivation of human plasminogen activator inhibitor-1 (PAI-1).

257 ata for the latency transition of the serpin plasminogen activator inhibitor-1 (PAI-1).

258 and both proteases are inhibited rapidly by plasminogen activator inhibitor-1 (PAI-1).

259 Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and

260 cript, identified by mRNA profiling, encoded plasminogen activator inhibitor-1 (PAI-1; SERPINE1).

261 in 6 patients, protein S deficiency in 4, a plasminogen-activator inhibitor-1 (PAI-1) deficiency in

262 ), inflammation (IL-6), or antifibrinolysis (plasminogen activator inhibitor-1 [PAI-1]) contribute to

263 (C-reactive protein [CRP], homocysteine, and plasminogen activator inhibitor-1 [PAI-1]), 3) products

264 P], renin, aldosterone), hemostatic factors (plasminogen activator inhibitor-1 [PAI-1]), inflammation

265 upling of TGF-beta to Smad2/3 activation and plasminogen activator inhibitor-1 (PAI1) expression, whi

266 d expression of TGF-beta downstream targets (plasminogen activator inhibitor-1, parathyroid hormone-r

267 ation of Smads 2 and 3 and activation of the plasminogen activator inhibitor-1 promoter (in NRP-154 a

268 sed transforming growth factor-beta-mediated plasminogen activator inhibitor-1 promoter activity in o

269 pitation showed reduced Smad3 binding to the plasminogen activator inhibitor-1 promoter in PTCs treat

270 on involves a functional polymorphism of the plasminogen activator inhibitor-1 promoter region and me

271 y reduced transactivation potential with the plasminogen activator inhibitor-1 promoters and behaved

272 d with significantly greater accumulation of plasminogen activator inhibitor-1 protein (PAI-1) (20.5

273 asmin complex, tissue plasminogen activator, plasminogen activator inhibitor-1, protein C, antithromb

274 tissue inhibitor of metalloproteinase-1 and plasminogen activator inhibitor-1 secretion in MDA-MB-23

275 S-1 peptide had increased efficacy in plasminogen activator inhibitor-1 serpin-deficient trans

276 ng strand 1C observed in a prelatent form of plasminogen activator inhibitor-1, since the (1)H NMR sp

277 matrix metalloproteinase-9, myeloperoxidase, plasminogen activator inhibitor-1, soluble E-selectin, s

278 ion of inflammatory mediators such as PAI-1 (plasminogen activator inhibitor 1), suggesting that gluc

279 the enzyme x inhibitor complex of tcu-PA and plasminogen activator inhibitor-1 (tcu-PA.PAI-1).

280 Increased transcription of the genes for plasminogen activator inhibitor 1, Tgf-beta1, Tgf-beta-i

281 of protein C and increased plasma levels of plasminogen activator inhibitor-1 that are independent r

282 tronectin was enhanced by uPA and blocked by plasminogen activator inhibitor-1, the latter approach a

283 estigate structure-function aspects of mouse plasminogen activator inhibitor-1, the recombinant prote

284 ingosine, and S1P induced gene expression of plasminogen activator inhibitor-1, TNF-alpha, monocyte c

285 addition, the use of exosites by maspin and plasminogen activator inhibitor-1 to indirectly affect p

286 mediated connective tissue growth factor and plasminogen activator inhibitor-1 up-regulation.

287 In contrast, both LOX-1 and CD32 mediate plasminogen activator inhibitor-1 upregulation in arteri

288 tasis, including TWIST1, fibronectin (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasmi

289 Plasminogen activator inhibitor 1, vascular cell adhesio

290 It was also demonstrated that the plasminogen activator inhibitor-1/vitronectin complex de

291 ed to augmented pressure (P=0.0003), whereas plasminogen activator inhibitor-1 was positively associa

292 mponents (analyzed as continuous variables), plasminogen activator inhibitor-1 was significantly and

293 plasminogen activator and elevated levels of plasminogen activator inhibitor 1 were observed.

294 Changes in interleukin-1B and plasminogen activator inhibitor-1 were apparent 24 hours

295 mplexes, plasminogen activator activity, and plasminogen activator inhibitor-1 were determined by mea

296 variate analysis, lower protein C and higher plasminogen activator inhibitor-1 were strong independen

297 uinating enzyme, represses the expression of plasminogen activator inhibitor-1, which is critical in

298 as observed, but a trend toward lower plasma plasminogen activator inhibitor 1 with higher excretion

299 vation with pan-arterial vascular stiffness, plasminogen activator inhibitor-1 with central vascular

300 onectin complex decreased the interaction of plasminogen activator inhibitor-1 with low density lipop